Data and Clinical Outcomes
DBS Therapy for Parkinson's Disease and Essential Tremor
The clinical use of implantable deep brain stimulation systems for Parkinson’s disease and essential tremor is supported by Medtronic clinical studies on DBS therapy for Parkinson's disease, and clinical studies on DBS therapy for tremor.
The Medtronic DBS Therapy Clinical Summary includes data from:
- Medtronic Parkinson’s Disease Global Clinical Study
- Comparison of Best Medical Therapy and Deep Brain Stimulation of Subthalamic Nucleus and Globus Pallidus for the Treatment of Parkinson’s Disease: Phase I
- US and European Tremor Trials
DBS Therapy for Dystonia
The effectiveness of Medtronic DBS Therapy System in treating dystonia has not been demonstrated in controlled clinical trials. The Medtronic DBS Therapy for Dystonia Clinical Summary contains information on documented clinical studies and case reports on dystonia patients that were not sponsored by Medtronic.The summary applies to Activa PC, Activa SC, and Soletra.
Provides an Additional 5.1 Hours of ''On'' Time1
Results from a prospective multi-center randomized controlled trial of patients with advanced Parkinson's disease showed that deep brain stimulation therapy with medications provided 5.1 hours of additional “on” time without dyskinesias compared to Best Medical Therapy (medications and nonpharmacological therapy) alone.1 The study also found that medications were reduced 25% on average for patients receiving DBS therapy.
Medtronic DBS Therapy Was Shown to Maintain Symptom Improvements up to 5 Years2
- Activa Therapy Clinical Summary, 2009.
- Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. November 2003;349(20):1925-1933.